News

Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has posted its protocol on www.ClinicalTrials.gov and is preparing to commence its pivotal Phase 3 study evaluating Trappsol® Cyclo™...

Tony Jellings: Former NPUK Trustee & Fundraising Coordinator

As we celebrate our milestone 30th year as a small charity, we are pleased to be joined by another instrumental former member of the Niemann-Pick UK Board of Trustees, Tony Jellings. Tony has kindly provided us with the following article which provides more detail surrounding his family's connection with Niemann-Pick disease, and his fantastic support throughout the years that followed...

Cyclo Therapeutics Inc: Update (13/4/21)

Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)

University College London begins preclinical studies to develop a treatment for Niemann Pick C disease with support from the Columbus Foundation